News
BMS gets new OK for Opdivo/Yervoy in kidney cancer
Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal
